Trial record 15 of 147 for:    marijuana | Closed Studies | United States

Stress and Marijuana Cue-elicited Craving and Reactivity

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Aimee McRae-Clark, Medical University of South Carolina
ClinicalTrials.gov Identifier:
NCT00613405
First received: February 11, 2008
Last updated: April 23, 2013
Last verified: April 2013
  Purpose

The purpose of this study is to explore the interaction between stress and marijuana cues, in hopes that it may lead to the development of new treatments for marijuana dependence.


Condition Intervention
Cannabis Use Disorders
Other: Stress + cue exposure
Other: No stress + cue exposure

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: Stress and Marijuana Cue-elicited Craving and Reactivity

Resource links provided by NLM:


Further study details as provided by Medical University of South Carolina:

Primary Outcome Measures:
  • Subjective Craving of Marijuana [ Time Frame: approx 2.5 hours (before, during and after exposure to stressor condition as well as exposure to neutral and marijuana-associated cues). ] [ Designated as safety issue: No ]
    Defined as the score on the Marijuana Craving Questionnaire (MCQ), range 7-84, higher scores indicate more craving


Secondary Outcome Measures:
  • Physiological Assessments: Serum Cortisol, ACTH, BP, HR, and GSR [ Time Frame: ~ 2.5 hours (before, during and after exposure to stressor condition as well as exposure to neutral and marijuana-associated cues). ] [ Designated as safety issue: No ]
  • Feelings of Stress/Anxiety as Measured by the State-Trait Inventory (STAI) [ Time Frame: ~2 hours ] [ Designated as safety issue: No ]
  • Current Mood as Assessed by the Mood Form [ Time Frame: ~2 hours ] [ Designated as safety issue: No ]

Enrollment: 87
Study Start Date: January 2008
Study Completion Date: May 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Stress + cue exposure
Individuals were exposed to the Trier Social Stress Test (TSST) as well as neutral cues and marijana cues.
Other: Stress + cue exposure
Trier Social Stress Task(TSST): subject is asked to give a talk and perform a math task in front of an audience, follwed by neutral and marijuana cue exposure.
Other Name: Stress stask, TSST
Experimental: No stress + cue exposure
Individuals were not exposed to a stress test, but were exposed to neutral cues and marijuana cues.
Other: No stress + cue exposure
Neutral and marijuana-associated cue exposure (scripted imagery, in vivo cues).
Other Name: marijuana cue exposure, neutral cue exposure

Detailed Description:

Although use of marijuana is widespread, little research has focused on the treatment of marijuana use disorders or on predictors of relapse. Although several factors contributing to relapse have been explored in other dependencies (i.e., alcohol, cocaine), little research has focused on drug cue-related or stress-induced relapse in marijuana-dependent individuals. Cue reactivity is a construct measured in a laboratory procedure where an individual's subjective, behavioral, and physiological responses are assessed following exposure to drug-related environmental cues or stressors. Investigating the effects of drug-related environmental cues and stress in marijuana-dependent individuals will be useful in guiding treatment development.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Meets Diagnostic and Statistical Methods (DSM)-IV Criteria for Marijuana Dependence
  • Between the ages of 18 and 65
  • Must abstain from marijuana use the day of testing and other drug use three days prior to testing

Exclusion Criteria:

  • Must not be taking any psychoactive medication, or medication that alters the hypothalamic pituitary adrenal (HPA) Axis functioning
  • Must not be taking any medications that alter heart rate or skin conductance monitoring
  • Cannot meet criteria for current major Axis I disorder (may alter response to stress)
  • Cannot be morbidly obese (Body Mass Index >39)
  • Cannot meet current abuse or dependence criteria of other substances in past 90 days
  • Must not have a medical condition that impacts HPA functioning (Hypertension, chronic pain, Addison's disease)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00613405

Locations
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
Sponsors and Collaborators
Medical University of South Carolina
Investigators
Principal Investigator: Aimee L McRae, PharmD, BCPP Medical University of South Carolina
  More Information

No publications provided

Responsible Party: Aimee McRae-Clark, Associate Professor of Psychiatry, Medical University of South Carolina
ClinicalTrials.gov Identifier: NCT00613405     History of Changes
Other Study ID Numbers: HR#17195, R21DA022424, R21-DA022424-01A1
Study First Received: February 11, 2008
Results First Received: June 15, 2011
Last Updated: April 23, 2013
Health Authority: United States: Federal Government
United States: Institutional Review Board

Keywords provided by Medical University of South Carolina:
substance-related disorders

ClinicalTrials.gov processed this record on July 22, 2014